Phase I Clinical Trial of Anlotinib in Progressive, Recurrent, and Refractory Sarcoma in Children
Status:
Not yet recruiting
Trial end date:
2022-12-30
Target enrollment:
Participant gender:
Summary
The purpose is to observe and evaluate the safety and effectiveness of anlotinib in children
with progressive, recurrent, and refractory sarcoma. Pharmacokinetics was also detected.